About Incyte Corporation
Incyte Corporation (INCY) has been publicly traded since 1993, making it a 33-year-old public company. It operates in the Biotechnology industry within the Healthcare sector. The company is headquartered in Wilmington, United States and employs approximately 2,844 people. With a market capitalization of $18 billion, INCY is a large established company.
Key Statistics
- Current Price
- $92.54
- Market Cap
- $18.42B
- 52-Week High
- $112.29
- 52-Week Low
- $53.56
- Sector
- Healthcare
- Industry
- Biotechnology
$1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -6.31% | $98.77 | $92.54 |
| 2025 | +43.00% | $69.07 | $98.77 |
| 2024 | +10.00% | $62.79 | $69.07 |
| 2023 | -21.83% | $80.32 | $62.79 |
| 2022 | +9.43% | $73.40 | $80.32 |
| 2021 | -15.61% | $86.98 | $73.40 |
| 2020 | -0.39% | $87.32 | $86.98 |
| 2019 | +37.32% | $63.59 | $87.32 |
| 2018 | -32.86% | $94.71 | $63.59 |
| 2017 | -5.55% | $100.27 | $94.71 |
| 2016 | -7.54% | $108.45 | $100.27 |
| 2015 | +48.34% | $73.11 | $108.45 |
| 2014 | +44.40% | $50.63 | $73.11 |
| 2013 | +204.82% | $16.61 | $50.63 |
| 2012 | +10.66% | $15.01 | $16.61 |
| 2011 | -9.36% | $16.56 | $15.01 |
| 2010 | +81.78% | $9.11 | $16.56 |
| 2009 | +140.37% | $3.79 | $9.11 |
| 2008 | -62.29% | $10.05 | $3.79 |
| 2007 | +72.09% | $5.84 | $10.05 |
| 2006 | +9.36% | $5.34 | $5.84 |
| 2005 | -46.55% | $9.99 | $5.34 |
| 2004 | +46.05% | $6.84 | $9.99 |
| 2003 | +50.00% | $4.56 | $6.84 |
| 2002 | -76.54% | $19.44 | $4.56 |
| 2001 | -21.85% | $24.88 | $19.44 |
| 2000 | -17.08% | $30.00 | $24.88 |
| 1999 | +60.54% | $18.69 | $30.00 |
| 1998 | -16.94% | $22.50 | $18.69 |
| 1997 | +74.76% | $12.88 | $22.50 |
| 1996 | +106.00% | $6.25 | $12.88 |
| 1995 | +80.18% | $3.47 | $6.25 |
| 1994 | +54.17% | $2.25 | $3.47 |
Valuation
INCY currently trades at a trailing P/E ratio of 14.4, which is considered low relative to the broader market. The forward P/E of 10.7 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 3.6. The price-to-sales ratio is 3.6.
Dividends
Incyte Corporation does not currently pay a dividend, choosing to reinvest earnings back into the business for growth.
Risk & Volatility
INCY has a beta of 0.84, indicating it is similarly volatile to the overall market. The stock's 52-week range is $53.56 to $112.29, and it currently trades in the upper half of its 52-week range.
Analyst Ratings
Based on 22 analyst opinions, INCY has a consensus "buy" rating. The average price target of $108.77 suggests 17.5% upside from current levels.
Frequently Asked Questions
What does Incyte Corporation do? ▼
Incyte Corporation is a Biotechnology company operating in the Healthcare sector. The company is headquartered in Wilmington, United States.
What sector is INCY in? ▼
INCY operates in the Healthcare sector, specifically in the Biotechnology industry.
When did INCY go public? ▼
Incyte Corporation went public in 1993, making it a 33-year-old public company as of 2026.
How much would $1,000 invested in INCY 5 years ago be worth today? ▼
A $1,000 investment in INCY five years ago would be worth approximately $1,170 today, representing a 17.0% return.
Does INCY pay dividends? ▼
No, Incyte Corporation does not currently pay a dividend. The company reinvests its earnings into growth.
What is INCY's market cap? ▼
Incyte Corporation has a market capitalization of $18 billion, classifying it as a large-cap company.
What is INCY's P/E ratio? ▼
INCY has a trailing P/E ratio of 14.4 and a forward P/E of 10.7, which measures how much investors are paying per dollar of earnings.
Is INCY a buy, hold, or sell? ▼
Based on 22 opinions, INCY has a consensus "buy" rating. The average price target is $108.77.
Last updated: 3/14/2026